Pfizer(US:PFE) Zhi Tong Cai Jing·2025-08-06 07:01Core Insights - Pfizer's CEO Albert Bourla emphasized a "special relationship" with President Trump, which was strengthened during the COVID-19 pandemic, facilitating direct discussions with the U.S. government regarding unfavorable factors for the company [1] - The pharmaceutical industry is currently awaiting the government's investigation results on how tariffs will be implemented, with over 90% of prescription drugs in the U.S. coming from generics, which are typically the cheapest [1] Group 1 - Bourla noted that Trump and other Washington officials are engaging in productive dialogues with industry leaders about tariffs and drug pricing issues [1] - The CEO mentioned that initial tariffs would be low, and a grace period was proposed during discussions with Trump and other government members [1] - The production of active pharmaceutical ingredients (APIs) is primarily based in Europe or Asia, which will be crucial when final tariff decisions are made [1] Group 2 - Pfizer received a letter from Trump requesting the company to lower drug prices for Medicare and Medicaid beneficiaries to align with the lowest prices paid in developed countries, known as "Most Favored Nation" (MFN) pricing [2] - The company is currently planning to implement price reduction measures and is exploring ways to mitigate negative impacts [2]